Nanjing Sanhome Pharmaceutical Co., Ltd.

Other

Sheng Bi

Yong Wang

Di Zhang

Liwen Zhao

Cang Zhang

Hongyan Chen

Yiping Gao

Yang Nan

Xian Zhang

Ye Edward Tian

Yang Liu

Suixiong Cai

Feng Yin

Haijun Dong

Lizhen Wu

Lijun Liu

Feng Wu

Lei Chen

Dezhong Wang

Yuxiu Li

Hongbin Chen

Zenghui Yu

A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof: 

Nucleoside phosphoramidate compound and use thereof

In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors. 

Heteroaryl alkyne compound and use thereof

Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar, Ar, R-Rare defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. 

3-aryl-6-aryl-[1,2,4]triazolo[4,3-&#x3b1;]pyridines as inhibitors of cell proliferation and the use thereof

Growing community of inventors

Jiangsu, China

Sheng Bi